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O R I G I N A L  R E S E A R C H
Cost-Effectiveness of Domiciliary High Flow Nasal 
Cannula Treatment in COPD Patients with Chronic 
Respiratory Failure
Sabrina Storgaard Sørensen 1 
Line Hust Storgaard 2 
Ulla Møller Weinreich 2,3
1Danish Center for Health Care 
Improvements, Department of Clinical 
Medicine, Aalborg University, Aalborg, 
Denmark; 2Department of Respiratory 
Diseases, Aalborg University Hospital, 
Aalborg, Denmark; 3Department of 
Clinical Medicine, Aalborg University, 
Aalborg, Denmark 
Purpose: To evaluate the cost-effectiveness of long-term domiciliary high flow nasal 
cannula (HFNC) treatment in COPD patients with chronic respiratory failure.
Patients and Methods: A cohort of 200 COPD patients were equally randomized into 
usual care ± HFNC and followed for 12 months. The outcome of the analysis was the 
incremental cost per quality-adjusted life-year (QALY) gained, and the analysis was con-
ducted from a healthcare sector perspective. Data on the patients’ health-related quality of 
life (HRQoL), gathered throughout the trial using the St. George’s Respiratory Questionnaire 
(SGRQ), was converted into EQ-5D-3L health state utility values. Costs were estimated 
using Danish registers and valued in British pounds (£) at price level 2019. Scenario analyses 
and probabilistic sensitivity analyses were conducted to assess the uncertainty of the results.
Results: The adjusted mean difference in QALYs between the HFNC group and the control 
group was 0.059 (95% CI: 0.017; 0.101), and the adjusted mean difference in total costs was 
£212 (95% CI: −1572; 1995). The analysis resulted in an incremental cost-effectiveness ratio 
(ICER) of £3605 per QALY gained. At threshold values of £20.000–30.000 per QALY 
gained, the intervention had an 83–92% probability of being cost-effective. The scenario 
analyses all revealed ICERs below the set threshold value and demonstrated the robustness 
of the main result.
Conclusion: This is the first cost-effectiveness study on domiciliary HFNC in Europe. The 
findings demonstrate that long-term domiciliary HFNC treatment is very likely to be a cost- 
effective addition to usual care for COPD patients with chronic respiratory failure. The 
results must be interpreted in light of the uncertainty associated with the indirect estimation 
of health state utilities.
Keywords: economic evaluation, quality-adjusted life years, QALY, health state utilities, 
EQ-5D, high flow heated and humidified oxygen, HFNC
Introduction
Chronic obstructive pulmonary disease (COPD) is a highly disabling disease 
characterized by persistent airflow limitation.1 The disease is the single most 
important respiratory disease globally, affecting approximately 384 million people 
worldwide.1 COPD has many well-documented negative impacts on the health 
status of the patients and health-care resources. Due to the irreversible decline in 
lung function, the disease impairs patients’ health-related quality of life 
(HRQoL)2–4 and results in numerous contacts to the health-care system, absentee-
ism, and an increasing need for help to carry out activities of daily living.5 Because 
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of this, COPD is a disease with a high socio-economic 
impact. In Denmark, COPD is estimated to account for 
approximately 10% of total health-care costs for treating 
patients of 40 years or more, amounting to closely 
2.5 billion Danish Kroner per year.6,7 The high costs are 
primarily driven by COPD exacerbations (AECOPD) 
requiring hospitalization,6,8–12 but also the use of primary 
care resources are considerable,13 and escalate with an 
increase in disease severity.14,15 Furthermore, expenses 
for home care are significantly higher in COPD patients 
compared to their peers.16,17
COPD is progressive by nature, however, early diag-
nosis and appropriate treatment can slow down the dete-
riorative process.18 Recently, it has been indicated that 
even in severely ill COPD patients with chronic respira-
tory failure, procrastination of disease progression can be 
obtained using long-term, domiciliary treatment with 
humidified high flow nasal cannula (HFNC).19,20 HFNC 
has been shown to reduce the number of exacerbations and 
number of hospitalizations and stabilize the quality of life 
in COPD patients.19,21,22 In addition, with long-term use, 
HFNC leads to a reduction in hypercapnia.23 However, the 
evidence of the cost-effectiveness of HFNC is less clear 
and has to date only been assessed in two studies; one 
being a study with only short-term follow-up and the other 
a study on a population of patients with various obstruc-
tive lung diseases.21,24
The purpose of the present study was to provide further 
evidence on the cost-effectiveness of domiciliary HFNC 
treatment by presenting the results of a post hoc cost- 
utility analysis of HFNC as an add-on treatment for 
patients with COPD and chronic hypoxic failure. The 
study was based on data from the only long-term, rando-
mized controlled trial on domiciliary HFNC for this 
patient group19 and is the first study to assess the cost- 
effectiveness of domiciliary HFNC in a European setting.
Methods
In the study, 200 COPD patients with chronic hypoxic 
failure living in the North Jutland Region of Denmark 
were included between December 2013 and July 2015. 
Inclusion criteria were chronic hypoxic failure (ie, three 
arterial blood gasses (ABG) during stable conditions 
demonstrating hypoxemia)25 and previously prescribed 
long-term oxygen therapy (LTOT) by a Pulmonary 
Medicine specialist. Exclusion criteria were malignant 
disease, terminal nonmalignant disease, unstable psychia-
tric disease, and long-term non-invasive ventilation (LT 
NIV). For further detail of the recruiting- and inclusion 
process, please see.19 Patients were randomized to either 
usual care, including LTOT as previously prescribed, or 
usual care plus HFNC (myAirvo™ 2 Humidified High 
Flow System (Fisher & Paykel Healthcare Ltd, 
Auckland, New Zealand)), which they were advised to 
use 8 hours per day, preferably during sleep. All patients 
were followed for 12 months. During the study, the 
patients had access to all their usual health-care services 
and medications.
Patients were informed according to the Helsinki 
Declaration and written informed consent was obtained before 
inclusion. Study approval was obtained from the North Jutland 
Ethical Committee (N-20,110,057), the Danish Data 
Protection Agency (2008–58-0028), and the study was regis-
tered at ClinicalTrials.gov (NCT 02731872).
Outcome Measure and Data Collection
Cost-effectiveness was assessed using a cost-utility analy-
sis (CUA), where the outcome measures used were health-
care sector costs and quality-adjusted life-years (QALYs). 
QALY is a combined measure that takes both the quality 
and quantity of life lived into account.26 The analysis was 
conducted as a within-trial analysis and was performed in 
accordance with international guidelines.26,27 The time 
horizon of the CUA followed that of the clinical trial, ie 
12 months; hence, no discounting was performed. All 
costs were calculated in 2019 values by use of the 
Danish Consumer price index. Costs were first calculated 
in Danish Kroner (DKK) but later converted to British 
pounds sterling (£) using an exchange rate of 877DKK 
per £100, as per December 31, 2019.28
Measure of Effectiveness
Information on the patients’ health-related quality of life 
(HRQoL) was gathered during the clinical trial using the 
St. George’s Respiratory Questionnaire (SGRQ), which is 
a disease-specific 40-item questionnaire designed to mea-
sure the HRQoL of COPD patients.29 The patients com-
pleted the questionnaire at scheduled in-clinic visits at 
baseline and after six and 12 months. Using a validated 
mapping algorithm,30 total SGRQ scores at the three time 
points were converted to health state utility values (EQ- 
5D-3L utility values) to calculate QALYs. Patients dying 
during the study received an EQ-5D-3L utility value of 
zero at the time of death. QALY was calculated using 
linear interpolation. Demographic data, such as age, sex, 
smoking status, etc., were also collected at baseline. Days 
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of treatment were registered by diary cards and were 
validated by data from the oxygen company. In case 
patients ceased using HFNC, they were asked to stay in 
the study during the 12 months.
Healthcare Service Use and Healthcare Costs
The analysis applied a Danish healthcare sector perspec-
tive; hence, the analysis included all costs related to pri-
mary care (general practice), secondary care (inpatient and 
outpatient hospital care), municipality-based health and 
social care (home nurse care, in-home assistance, house-
hold cleaning, and rehabilitation), costs associated with 
purchases of prescription medicine, and intervention 
costs. Costs borne by the patient or relatives were not 
included. The analysis only included disease-specific 
costs, except for general practice care and municipality- 
based care costs. It was not possible to distinguish between 
disease-specific and general resource use within those set-
tings. Costs were gathered 12 months pre-study and during 
the 12 months study period. An overview of the different 
costs included in the analysis can be seen in Appendix A.
The patient-specific cost data were extracted from vali-
dated Danish registries using a unique personal identifica-
tion number that each Danish citizen has. The personal 
identification number makes it possible to link individual 
data between registries. Data on primary and secondary 
healthcare resource use were extracted from the Northern 
Jutland Region registry. As for general practice, the date 
for each contact and type of service provided was listed in 
the register, and each contact was valued based on fees 
negotiated in a collective agreement with the Danish 
Medical Association.31 In the register, it was not possible 
to identify the cause of contact to general practice; hence, 
all contacts were included in the analysis. As for contacts 
in the secondary healthcare sector, the register provided 
information on the date of each contact, the diagnosis 
leading to the contact, procedures performed, and length 
of stay in case of an admission. Each contact was classi-
fied and valued according to the Danish diagnosis-related 
grouping (DRG) system.32
Data on the patients’ use of prescribed inhalation med-
icine (long-acting muscarinic agonist (LAMA) plus long- 
acting β2 agonist (LABA) plus inhaled corticosteroid 
(ICS); LAMA/LABA; LAMA/ICS or LABA/ICS; 
LAMA; LABA; ICS; SABA only); oral corticosteroids 
and antibiotics was gathered from the Danish 
Prescription Registry. The Anatomical Therapeutic 
Chemical Classification System (ACT) numbers included 
in the analysis are provided in Appendix B. The data 
included information on the date the medicine was 
redeemed at the pharmacy and type, number of packages 
issued, and cost of the medicine. The cost for prescription 
medicine was valued according to standardized pharmacy 
consumer prices and did not include the out-of-pocket 
expenses paid by the patients.33
The resource use of community care was estimated 
based on registrations from Aalborg Municipality, which 
is the largest municipality in the Region of Northern 
Jutland. Of the patients included in the study, 54% 
(n=108) lived in Aalborg Municipality during the trial, 
and the patients were equally distributed between the two 
groups. The registered time consumption for each care 
category was valued using average national effective 
hourly wage rates to increase generalizability to other 
Danish settings.34
Intervention Costs
Costs for the myAIRVO™ 2 and consumables were esti-
mated in collaboration with the manufacturer (Fisher & 
Paykel Healthcare Ltd, Auckland, New Zealand), and the 
costs represented mean European prices. The cost for the 
myAIRVO™ 2 device was annuitized using an interest 
rate of 4% and assuming a 5-year lifetime of the device, 
as estimated by the manufacturer. The yearly cost for 
consumables included six breathing tubes, six autofill 
chambers, and 12 OptiflowTM nasal cannulas. Additional 
intervention costs included cost for setup, service, and an 
oxygen stand, delivered by the patients’ usual oxygen 
supply company (AGA Linde HealthCare, Fredericia, 
Denmark), based on Danish prices. The yearly cost for 
setup and service was calculated as an average of prices 
paid over the last five years. The oxygen stand was like-
wise annuitized using an interest rate of 4% and assuming 
a 5-year lifetime. The intervention costs did not include 
costs for LTOT, as this was similar in both the HFNC- 
group and controls. In Denmark, the cost for oxygen use is 
not per liter of oxygen used but for the service of oxygen 
delivery to the patient. Costs for water and electricity were 
considered insignificant and, hence, not included in the 
analysis.
Statistical Analysis
The analysis was conducted using the principles of inten-
tion-to-treat. Missing data were assumed to be missing at 
random (MAR), and multiple imputation was applied 
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according to guideline.35 A description of the imputation 
model can be found in Appendix C.
Participant baseline data were provided as mean ± the 
associated standard deviation (SD) or absolute numbers. 
Raw between-group differences were evaluated at 
a significance level of p <0.05.
The cost-effectiveness of HFNC treatment was 
assessed by calculating the incremental cost-effectiveness 
ratio (ICER), ie, calculating the mean difference in costs 
divided by the mean difference in QALYs between the 
HFNC group and the control group.26 The incremental 
estimates of QALYs and costs were assessed using regres-
sion analysis, more specifically generalized linear models 
(GLMs).36 Several GLMs with different distributions and 
link functions were tested for QALYs and costs to ensure 
the most appropriate model fit. For QALYs, a GLM with 
Gaussian distribution and identity-link (ie ordinary least 
squares model) turned out to be the best fit as data fol-
lowed a normal distribution. Due to the right-skewed 
distribution of the cost data, a GLM with gamma distribu-
tion and identity-link was chosen. To heighten the preci-
sion of the QALY and cost point estimates, baseline 
covariates were applied to the regression models. 
A patient’s baseline utility is highly correlated with his 
or her QALYs over the given follow-up period, and failure 
to correct for any imbalance in baseline mean utilities, 
irrespective of whether the differences are statistically 
significant or not, will lead to incorrect results.37 As 
such, in the base case analysis QALYs were corrected 
for baseline EQ-5D-3L utility, and total costs were cor-
rected for baseline total costs in the 12 months before 
recruitment, as prescribed by published literature.37,38 
Additionally, both outcomes were corrected for days of 
HFNC treatment in the study. Should the results of the 
unadjusted analyses be of interest to the reader, they can 
be assessed at.39
In addition to the base case analysis, four scenario 
analyses were performed to assess the uncertainty sur-
rounding the point estimates of QALYs and costs. Like 
the base case analysis, the four scenario analyses were 
performed using GLM regression analysis. Except for 
scenario analysis one, all analyses were corrected for the 
same covariates as the base case analysis. Scenario analy-
sis one was conducted to assess the impact of correcting 
for treatment days. As such, QALYs were only corrected 
for baseline EQ-5D-3L utility value, and total costs were 
only corrected for baseline total costs in the 12 months 
before recruitment in scenario one. The second and third 
scenario analysis assessed how much it influenced results 
if the intervention cost was 30% lower vs 30% higher, 
respectively than the estimate used in the base case analy-
sis. The fourth scenario analysis was conducted as 
a complete case analysis to assess the impact of the impu-
tation model on results.
To evaluate the decision uncertainty, probabilistic sen-
sitivity analysis (PSA) was performed on the base case 
analysis and the scenario analyses by drawing 10,000 
random trial simulations. A PSA is used to assess the 
impact of various uncertainties in parameter values on 
the probability of the intervention being cost-effective at 
different cost-effectiveness threshold values.36 Variance- 
covariance matrices were extracted from the regression 
of QALYs and costs, and Cholesky’s decomposition was 
applied to ensure correlation between the random draws. 
The simulations were used to generate incremental cost- 
effectiveness scatter plots and cost-effectiveness accept-
ability curves. The results of the PSA were presented at 
assumed cost-effectiveness threshold values of £20,000–-
30,000 per QALY gained.
All statistical analyses were performed in STATA ver-
sion 15.1 and Microsoft Excel® 2016.
Results
All 200 recruited patients were included in the analysis. 
Patient baseline characteristics are listed in Table 1. No 
significant differences were seen between the two groups 
except for mMRC, where the HFNC group demonstrated 
a significantly higher score than the control group. Overall, 
the HFNC group presented with a considerably higher total 
mean cost in the year preceding recruitment when compared 
to the control group. The baseline variables with missing data 
were SGRQ (2% missing) and municipality costs (50% 
missing, including eight patients living in Aalborg 
Municipality). Patients from Aalborg Municipality did not 
differentiate on any demographic data from patients from the 
other participating municipalities.
HFNC treatment was on average used for 248 days, six 
hours/day, during the 12 months study period. Within the 
first month, 14% of the HFNC treated patients stopped 
using the device, and of those, 3% left the study. On 
average, the remaining 86% used HFNC for 286 days, 7 
hours/day. By the end of the study, 33% of the HFNC 
group and 29% of the control group had left the study, 
including those who died. The mortality was similar 
between the two groups, with 15 deaths in the HFNC 
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group and 12 deaths in the control group. Further details 
from the clinical study can be found elsewhere.19
Table 2 presents the raw non-imputed and unadjusted EQ- 
5D utility values for the HFNC group and the control group at 
baseline, six months, and 12 months. As demonstrated, the 
amount of missing data increased to 23% and 20% at six and 
12 months. At baseline, the HFNC group had a somewhat 
lower utility value than the control group; however, at six and 
12 months of follow-up, the utility values for the HFNC group 
were higher than the mean utility value in the control group. 
Both groups, however, suffered a decline in HRQoL during 
the study period, except at six months, where the mean utility 
value was stagnant for the HFNC group.
Except for municipality data, there were no missing data 
on costs as data were drawn from personally identifiable 
registers. Table 3 lists the resource consumption within the 
12 months of follow-up and associated unit costs. As demon-
strated, no significant differences could be observed between 
the HFNC group and the control group. It is also evident from 
the table that patients in both groups experienced almost no 
emergency room visits in the follow-up period. Table 4 pre-
sents the mean unadjusted costs per person in each group for 
all cost categories within the 12 months of follow-up. 
Compared to the control group, the HFNC group presented 
with a somewhat higher mean cost for hospital admission, but 
at the same time presented with a lower municipality cost. 
When including the intervention cost of £1235,85 per patient, 
the mean unadjusted total costs were higher in the HFNC 
group than in the control group, leading to a total raw differ-
ence of £788.57 per year.
Cost-Effectiveness
Table 5 presents the cost-effectiveness results of the base 
case analysis and the scenario analyses. When adjusting 
for baseline imbalances in the base case analysis, the 
difference in QALYs between the HFNC group and the 
Table 1 Background Information on Total Study Population at Baseline
Study Population HFNC- 
Treated (n=100)
Controls (n=100) Raw Between-Group 
Difference
P-value for Group 
Difference
Gender, female, n 56 63 −7 NS
Age, years 71.0 (8.2) 70.4 (9.0) 0.6 NS
Treated with LTOT prior to inclusion, months 28.9 (32.6) 33.5 (30.6) −4.6 NS
FEV1% 29.8 (12.6) 31.8 (12.9) −1.8 NS
Smoking status, n, never/ present /former 1/14/85 0/26/74 1/-12/11 NS
Pack-years 41.7 (17.8) 40.5 (19.5) 1.2 NS
mMRC score 3.3 (0.9) 2.9 (0.9) 0.4 0.008
Total SGRQ score 63.1 (14.5) 60.8 (13.4) 2.3 NS
Exacerbations in year preceding inclusion 3.2 (3.1) 2.9 (2.8) 0.3 NS
Number of admissions in year preceding inclusion 1.08 (1.53) 0.89 (1.48) 0.18 NS
Days of admission in year preceding inclusion 7.40 (11.21) 5.27 (8.66) 2.13 NS
Number of ER visits in year preceding inclusion 0.02 (0.01) 0.02 (0.01) 0 NS
Costs in year preceding inclusion, excl. 
municipality costs (£)*
6146 (5410) 5346 (5351) 800 NS
Municipality costs in year preceding inclusion (£) 1696 (2402) 1998 (2054) −302 NS
Notes: Results presented as mean with standard deviation (SD) unless otherwise stated. The table has partially been reproduced from a previously published paper with 
permission from copyright holder.19 *Variable has no missing values. Data were not complete for the following variables: SGRQ (HFNC-treated: n=97, control: n=99), 
Municipality costs in year preceding treatment: (HFNC-treated: n=51, control: n=49) 
Abbreviations: ER, emergency room; FEV1, forced expiratory volume in the first second; GP, general practitioner; HFNC, humidified high-flow nasal cannula; LTOT, long 
term oxygen treatment; SGRQ, St George Respiratory Questionnaire.
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control group was 0.059 (95% CI: 0.017; 0.101), indicat-
ing a significant mean gain in HRQoL for patients receiv-
ing HFNC treatment. The adjusted difference in costs 
was £212 (95% CI: −1572; 1995), indicating a non-sig-
nificant increase in total mean costs per patient in the 
HFNC group. The base case analysis resulted in an ICER 
of £3605 per QALY gained, which is considered cost- 
effective at the given cost-effectiveness threshold value 
of £20.000–30.000 per QALY gained. The incremental 
cost-effectiveness scatter plot in Figure 1 presents the 
result of the PSA. The simulations are primarily plotted 
in the northeast and southeast quadrants, which agree 
with the HFNC treatment leading to a significant QALY 
gain at a small and insignificant increase in costs. The 
PSA of the base case analysis revealed that HFNC treat-
ment was found to be cost-effective in 83% to 92% of the 
simulations at cost-effectiveness threshold values of 
£20.000–30.000 per QALY gained, respectively.
The scenario analyses all found HFNC treatment to be 
associated with a gain in QALYs, and all except scenario 
analysis 1 found the QALY gain to be significant. The 
HFNC treatment was associated with a slight insignificant 
increase in cost for all analyses, except scenario analysis 
two that found the intervention to be cost-saving when 
compared to the control group. The cost-effectiveness 
result was relatively robust across the scenario analyses, 
demonstrating ICERs below the set cost-effectiveness 
threshold values and high probabilities of being cost-effec-
tive based on the PSA.
Discussion
This study evaluated the cost-effectiveness of HFNC treat-
ment for patients with severe COPD and persistent respiratory 
failure in a Danish setting. This is the first cost-effectiveness 
study on HFNC in Europe and, to our knowledge, the first 
long-term study in COPD patients. The base case analysis 
resulted in an ICER of £3605 per QALY gained, and an 
83–92% probability of being cost-effective at threshold values 
of £20.000–30.000 per QALY gained. Hence, HFNC treat-
ment was demonstrated to be highly cost-effective when com-
pared to usual practice. The findings from the scenario 
analyses were consistent with the result of the base case 
analysis, with all analyses demonstrating ICERs way below 
the set cost-effectiveness threshold.
In this study, the raw cost for COPD-related hospital 
admissions was higher in the HFNC group than in the 
control group within the 12 months of follow-up. 
Previously, a reduction in COPD-related admissions was 
found with increased use of HFNC.19 As the use of HFNC 
treatment varied much, and 14% of the patients stopped 
using the device within the first month after initiating 
treatment, correction for treatment days is believed to be 
of utmost importance when evaluating the cost- 
Table 2 Non-Imputed and Unadjusted EQ-5D-3L Utility Values for the HFNC-Treated Group and the Control Group at Baseline, Six 
Months, and 12 Months of Follow-Up
HFNC-Treated Controls Raw Between-Group Difference value for Group Difference
Baseline
N 97 99
Missing (%) 1.5% 0.5%
EQ-5D-3L utility value 0.470 (0.196) 0.504 (0.174) −0.034 0.202
Six months
N 76 79
Missing (%) 12% 11%
EQ-5D-3L utility value 0.469 (0.214) 0.433 (0.209) 0.036 0.289
12 months
N 78 82
Missing (%) 11% 9%
EQ-5D-3L utility value 0.378 (0.243) 0.372 (0.242) 0.006 0.894
Notes: Patients dying during the study were assigned an EQ-5D-3L utility value of zero, and hence are not listed as missing. Values are presented as mean with standard 
deviation (SD). 
Abbreviation: HFNC, humidified high-flow nasal cannula.
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effectiveness of HFNC. It is worth noting; however, that 
cost-effectiveness was still demonstrated in scenario ana-
lysis 1, where no correction for treatment days was made.
The complete case analysis revealed an incremental 
QALY estimate that was relatively higher than for the 
base case analysis and the other scenario analyses. In 
a complete case analysis, it is assumed that data are miss-
ing completely at random and that the included patients 
are representative of those with missing data. However, 
a descriptive analysis of the missing data revealed that 
data were more likely to be missing at random. On these 
grounds, it was chosen to use the imputed dataset for the 
base case analysis, as the complete case analysis most 
likely provides a result that is not representative of the 
entire study population.
The vigilant reader will have noticed a discrepancy 
between the developments in HRQoL presented in the original 
study vs in the present study. Even though the analyses are 
based on the same data, the findings cannot be directly com-
pared for two reasons. First, the HRQoL data presented in the 
original study had been adjusted for the use of HFNC, whereas 
the data listed in Table 2 are presented as raw data. Second, the 
Table 3 Non-Imputed and Unadjusted Mean Resource Utilization per Patient for the HFNC-Treated Group and the Control Group 
Over the 12-Month Follow-Up and Applied Unit Costs
Category HFNC- 
Treated






Mean resource utilization (SE) per patient
Primary care
Number of general 
practitioner contacts
33.00 (2.24) 33.66 (2.39) −0.66 0.99 Per contact Tariffs from collective 
agreement31
Secondary care
Number of hospital 
admissions
0.87 (0.14) 0.81 (0.13) 0.06 0.63 Per contact DRG value of contact32
Number of hospital bed 
days
6.14 (1.18) 6.06 (1.04) 0.08 0.73 Per contact Included in DRG value of 
contact32
Number of hospital ER 
visits
0.01 (0.01) 0.05 (0.03) −0.04 0.31 Per contact DRG value of contact32
Number of hospital 
outpatient visits
1.21 (0.09) 1.61 (0.14) −0.40 0.11 Per contact DRG value of contact32
Medicine
Number of packages of 
prescription drugs




Hours of home nurse 
care
5.47 (1.19) 4.94 (1.05) 0.53 0.64 Per hour National average effective 
hourly wage rate (£32)34
Hours of in-home 
assistance
27.58 (7.65) 31.67 (7.44) −4.09 0.48 Per hour National average effective 
hourly wage rate (£28)34
Hours of cleaning 5.33 (1.30) 8.48 (1.54) −3.15 0.12 Per hour National average effective 
hourly wage rate (£23)34
Hours of training/ 
rehabilitation
2.70 (0.89) 2.02 (0.55) 0.68 0.80 Per hour National average effective 
hourly wage rate (£32)34
Notes: Data are complete for all categories except for data on resource consumption related to municipality care (50% missing). 
Abbreviations: DRG, diagnosis-related grouping; ER, emergency room; HFNC, humidified high-flow nasal cannula; SE, standard error.
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Table 4 Unadjusted Mean Costs (£) per Patient in the HNFC-Treated Group and the Control Group Over the 12-Month Follow-Up 
Presented into Cost Categories
Category HFNC- 
Treated
Controls Raw Between-Group 
Difference
P-value for Group 
Difference
Mean costs (SE) per patient, £
General practitioner contacts 348.01 (26.01) 363.07 (28.73) −15.06 0.91
Hospital admissions 3349.72 (546.67) 3045.32 (481.38) 304.40 0.60
Hospital ER visits 0.86 (0.86) 3.22 (2.12) −2.36 0.32
Hospital outpatient visits 312.44 (23.55) 383.70 (32.56) −71.26 0.16
Prescription medicine 1534.98 (78.96) 1653.24 (142.82) −118.26 0.87
Municipality care* (imputed) 2129.28 (511.22) 2673.97 (374.97) −544.69 0.29
Intervention cost
-myAirvo device** 425.69 0 425.69
-Oxygen stand** 37.81 0 37.81
-Consumables 493.50 0 493.50
-Service 278.85 0 278.85
Total cost (incl. intervention 
costs)
8911.09 (918.89) 8122.52 (657.35) 788.57 0.39
Notes: Data were complete for all categories except for data on costs related to municipality care (50% missing). *Covers the services of home nurse care, home 
assistance, cleaning, and rehabilitation. **Annuitized over a 5-year period at a discount rate of 4%. 
Abbreviations: ER, emergency room; HFNC, humidified high-flow nasal cannula; SE, standard error.
Table 5 Incremental Cost-Effectiveness Ratios (ICERs) for the Base Case Analysis and Scenario Analyses
Analysis N Incremental 







Probability of Being Cost-Effective at 
Thresholds of £20,000-£30,000/QALY
Base case analysis 200 212 (−1572;1995) 0.059 (0.017;0.101) 3605 83–92%
Scenario I
Analysis without 
adjustment for treatment 
days




Analysis with 30% lower 
intervention cost
200 −172 (−1957;1613) 0.059 (0.017;0.101) −2926 90–96%
Scenario III
Analysis with 30% higher 
intervention cost
200 596 (−1187;2378) 0.059 (0.017;0.101) 10,146 72–85%
Scenario IV
Complete case analysis 63 9 (−2575;2594) 0.103 (0.038;0.167) 92 91–97%
Notes: The incremental cost and incremental QALY are calculated as the difference between the HFNC group and the control group. The probability of cost-effectiveness is 
presented at thresholds of £20,000 and £30,000, respectively. 
Abbreviations: CI, confidence interval; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.
https://doi.org/10.2147/CEOR.S312523                                                                                                                                                                                                                                
DovePress                                                                                                                                 
ClinicoEconomics and Outcomes Research 2021:13 560
Sørensen et al                                                                                                                                                        Dovepress






































































HRQoL data in Table 2 includes the patients who died during 
the study. Those patients were assigned an EQ-5D-3L utility 
value of zero at the time of death, as it is the practice in 
calculating QALYs. This naturally affects the estimated 
HRQoL in both groups.
Both patient groups had very few emergency room (ER) 
visits in the year before inclusion and during the trial period. 
This is inconsistent with previous findings in COPD 
patients.40,41 There may be several, possibly inter-related 
explanations for this. For one, in the North Jutland Region of 
Denmark, where the trial was carried out, telehealth care 
(THC) is commonly used in the care of COPD patients. THC 
has, in a recent review by O’Connor, been suggested to reduce 
ER visits.42 Secondly, in Denmark, patients should be referred 
to the ER by the general practitioners, who also have an on-call 
shared duty out of office hours. Moderate exacerbations will, 
therefore, often be handled in this setting. Please note that costs 
for the on-call visits are included in general practitioner 
expenses in this analysis. Thirdly, most contacts to the ER 
lead to hospital admissions in this cohort of severely ill 
COPD patients, and as such, were not registered as ER visits.
A particular strength of the study was the nearly com-
plete data on resource use. Most data were retrieved from 
well-validated Danish registries, which enables the estima-
tion of costs with great accuracy. Municipality costs were 
estimated based on register data from Aalborg 
Municipality due to difficulties in retrieving data on 
resource use from the other municipalities. As more than 
half the patients included in the study lived in Aalborg 
Municipality, and they did not differ demographically at 
baseline from patients living in the other participating 
municipalities, multiple imputation was used to generate 
plausible imputed data for the entire population.
Economic evaluation of devices often raises methodologi-
cal challenges that are overlooked by international guidelines 
for economic evaluation, as they have been written with phar-
maceuticals in mind.43 One of such challenges is the estimation 
of the cost of the device, as prices often change over time due to 
iterative product developments, market dynamics, and differ-
ences in how devices are procured in healthcare systems. 
Changes in costs may affect cost-effectiveness and, ultimately, 
decisions about adoption. Another strength of this study was, 
therefore, the examination of how price variation of the device 
and associated service affected the estimate of cost-effective-
ness in scenario analysis 2 and 3. When the intervention cost 
was lowered by 30%, HNFC was a dominant treatment strat-
egy compared to usual practice. Applying a 30% higher inter-
vention cost resulted in an ICER of £10,146 per QALY gained, 
which is still considered cost-effective at the given cost-effec-
tiveness threshold value. It should also be highlighted that the 
price of the device represented mean European prices, which is 
believed to improve the generalizability of the findings to other 
Figure 1 Incremental cost-effectiveness scatterplot based on the probabilistic sensitivity analysis for the base case analysis. 
Notes: The black line illustrates acost-effectiveness threshold value of £20,000per QALY gained. 
Abbreviation: QALY, quality-adjusted lifeyear.
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European settings. Even though efforts were made, it was not 
possible to obtain European prices for service due to different 
providers and setups. As such, the cost for service was esti-
mated based on Danish prices. Generalizability of cost-effec-
tiveness analyses to other countries can also be challenging due 
to differences in, eg, healthcare costs and organization of 
healthcare. Denmark has a well-established public healthcare 
system and a very systematic and well-developed system for 
COPD management, and costs for COPD care are therefore 
considerable. However, due to the transparent reporting of the 
methods used in this study, it is believed that decision-makers 
will be able to recognize similarities and differences in costs 
and thereby determine whether the findings can relate to their 
setting.
In this study, the study population consisted of patients with 
severe COPD and persistent respiratory failure; the patients 
had on average suffered from chronic respiratory failure for 
about two-and-a-half years and were therefore approaching 
palliative care. A cost-effective treatment for this disease 
severity is rarely seen. To date, only one other study by 
Milne et al24 has assessed the costs of long-term domiciliary 
HFNC. The modest-sized study, including patients with differ-
ent obstructive lung diseases of mixed severity, using the 
device for an average of 1.6 hours per day, found domiciliary 
HFNC to be moderately cost-effective.24 The present study, 
including more than twice as many patients using the device on 
average six hours per day, is, therefore, a strong improvement 
in evidence of the cost-effectiveness of domiciliary HFNC. In 
domiciliary non-invasive ventilation, another add-on treatment 
for severely ill COPD patients, there are indications of cost- 
utility.44,45 The few studies that exist, however, are small, of 
variable quality or merely theoretical.44,45 Domiciliary HFNC 
is an emerging add-on to COPD patients with persistent 
respiratory failure, with strong indications of reducing dys-
pnea, reduction in exacerbation rates, and improved 
HRQoL.19,21,46–48 In contrast to domiciliary non-invasive 
ventilation,49 guidelines do not recommend using HFNC as 
an add-on treatment for severely ill COPD patients, and indica-
tions of cost-utility are therefore of utmost importance. This 
paper is therefore considered a sound contribution for possible 
future recommendations of HFNC.
There are, of course, limitations to this study. Theoretically, 
care organization may differ between municipalities, which 
could influence municipality costs; however, care orchestration 
in Denmark is generally very much aligned. The main limita-
tion of this study was, however, the use of mapping to estimate 
EQ-5D-3L utility values from the SGRQ. The use of mapping 
poses a degree of uncertainty on its own. As such, it is generally 
advised that utility scores are measured as accurately as possi-
ble by the collection of HRQoL data during the clinical trial 
using a utility-based measure such as the EQ-5D.30 At present, 
there exists no mapping algorithm from SGRQ to EQ-5D for 
Denmark, and instead, a validated mapping algorithm based on 
UK EQ-5D-3L population preferences was used.30 Country- 
specific value sets should preferably be used to evaluate treat-
ment effects, as differences can exist between countries on how 
value sets are generated and populations’ preferences for health 
states.50,51 However, high and significant correlations have 
been demonstrated between the UK, and the Danish EQ-5D- 
3L value sets,52 which supports the use of the algorithm in 
a Danish context.
Conclusion
This study demonstrates that domiciliary HFNC is likely 
to be highly cost-effective for patients with severe COPD 
and persistent respiratory failure compared to usual prac-
tice. Despite the uncertainties associated with the indirect 
estimation of health state utility values, the study delivers 
a robust estimate for possible future recommendations of 
domiciliary HFNC treatment in these severely ill patients.
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